Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Account Payables (2016 - 2025)

Syndax Pharmaceuticals has reported Change in Account Payables over the past 11 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $2.8 million for Q4 2025, down 59.07% from a year ago — trailing twelve months through Dec 2025 was $5.0 million (up 197.54% YoY), and the annual figure for FY2025 was $5.0 million, up 197.54%.
  • Change in Account Payables for Q4 2025 was $2.8 million at Syndax Pharmaceuticals, up from -$3.5 million in the prior quarter.
  • Over the last five years, Change in Account Payables for SNDX hit a ceiling of $7.3 million in Q2 2025 and a floor of -$6.7 million in Q3 2024.
  • Median Change in Account Payables over the past 5 years was $1.1 million (2021), compared with a mean of $653600.0.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 266.77% in 2021 and later plummeted 829.29% in 2023.
  • Syndax Pharmaceuticals' Change in Account Payables stood at $547000.0 in 2021, then plummeted by 605.3% to -$2.8 million in 2022, then soared by 241.53% to $3.9 million in 2023, then skyrocketed by 71.98% to $6.7 million in 2024, then tumbled by 59.07% to $2.8 million in 2025.
  • The last three reported values for Change in Account Payables were $2.8 million (Q4 2025), -$3.5 million (Q3 2025), and $7.3 million (Q2 2025) per Business Quant data.